CA-PATIENT-SAFETY
3.2.2020 15:02:07 CET | Business Wire | Press release
Patient Safety Movement Foundation is urging clinicians, patient advocates, hospitals and medical technology companies to support Data Sharing as part of the 2020 Federal Health IT plan.
“One of the key ways to combat preventable patient deaths in hospitals is for companies to share their data in a HIPAA compliant manner instead of hoarding it for profit. The plan proposed by the Office of the National Coordinator for Health Information Technology will help create the personalized patient data superhighway we need to reduce and eliminate preventable deaths in our hospitals,” said Joe Kiani, Founder of the Patient Safety Movement and Founder, Chairman, and CEO of Masimo. “If we block patient data, no one can create algorithms that can warn clinicians of potential problems before they happen. We are already losing way too many people to medical errors in our hospitals each year, and we can’t delay this any longer.”
Several years ago, a young man named Rory Staunton died of Sepsis because of exactly this type of fragmented medical information system. “On Tuesday, my son Rory was playing basketball at a school gym, fell and cut himself. His teacher put a bandaid on it. He died 5 days later from Sepsis,” said Orlaith Staunton. “Despite having a high heart rate for his size as measured by a patient monitor at his pediatrician’s office and a high white blood cell count that was detected in the Emergency Department’s blood test machine, Rory was sent home because no one had all of the details of his problems and care. They couldn’t put the high heart rate and high white blood cell count together with the full story to realize he had Sepsis. Had we had data sharing allowing a complete view of his history and condition or the benefit of a predictive algorithm to track my son’s case when he was connected to various monitors and blood test machines, he would probably be alive today.”
Since the founding of the Patient Safety Movement, nearly 100 companies have signed the voluntary Open Data Pledge, including Baxter, Cerner, Dräger, Edwards Lifesciences, GE Healthcare, IBM, Masimo, Medtronic, Oracle, Philips and Zoll. Complete list below. For more information on how you can sign the Pledge, please visit www.patientsafetymovement.org . For more information regarding the 2020 Federal Health IT Plan, please visit https://www.healthit.gov/sites/default/files/page/2020-01/2020-2025FederalHealthIT%20StrategicPlan_0.pdf .
Companies that have signed the Patient Safety Movement Foundation Open Data Pledge (alphabetical order):
AccuHealth Group |
Admetsys |
AirStrip |
Ambient Clinical |
Baxter |
BD Intelliport (formerly CRISI Medical Systems) |
Bernoulli Health |
Beterra Health |
BIOIN SOLUCIONES SAS |
Biovigil |
BrainStem Biometrics |
caresyntax, Inc. |
Cercacor |
Cerner |
Cheetah Medical, Inc. |
Clean Hands-Safe Hands |
CNSystems Medizintechnik AG |
Codonics |
CrossChx |
DebMed |
Decisio Health |
Deltex Medical |
Doctella |
Dräger |
DynaLabs LLC |
11 Health |
EarlySense |
eBroselow, LLC |
Edwards LifeSciences |
Forcare |
FUJIFILM SonoSite, Inc. |
GE Healthcare |
Genomi-k |
Hamilton Medical AG |
Handtevy-Pediatric Emergency Standards, Inc. |
Healthcentrix |
Heartin Inc. |
HeROScore |
Hiteks |
IBM Watson Health |
ICUcare |
Informs Inc. |
Innara Health |
Iradimed |
Jvion |
KnectIQ Inc. |
Kolkin |
LiDCO Group |
LumiraDX USA Inc. |
Magnamed Tecnologia Médica S/A. |
Masimo |
Mdoloris Medical Systems |
Medi+Sign |
Medical Simulation Corporation |
MediSafe Inc |
Medtronic |
Mindray |
Modulated Imaging |
Monarch Medical Technologies |
Neosim |
NeurOptics |
Oracle |
Patient Valet |
Pegwin |
PeraHealth |
PerceptiMed |
Philips Healthcare |
Phoenix Medical Systems Pvt. Ltd. |
Pieces Technology |
Pooyandegan Rah Saadat Co.,Ltd. |
Rapid Healthcare |
Redivus Health |
RGP Healthcare |
RightPatient |
RPRD Diagnostics |
SafeCare Group |
SafeStart Medical |
SenTec Inc. |
Smiths Medical |
Sotera Wireless |
Stanley Healthcare |
Stibo Systems |
SurgiCount Medical |
SwipeSense |
Talis Clinical |
ThermoMedics, Inc. |
Triton Electronic Systems LTD |
True Process |
Vitalacy (FORMERLY Hygenix) |
Welch Allyn (acquired by Hill-Rom) |
West-Com Nurse Call Systems, Inc |
ZOLL Medical |
About Patient Safety Movement Foundation
Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit that offers free tools to help achieve ZERO preventable deaths from hospital errors. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO. Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. PSMF’s World Patient Safety, Science & Technology Summit brings together the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. Our Actionable Patient Safety Solutions (APSS) provide evidence-based processes to help hospitals eliminate errors. Our Open Data Pledge encourages healthcare technology companies to share the data for which their products are purchased. Visit patientsafetymovement.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
